$4.65
-0.10 (-2.11%)
Open$4.75
Previous Close$4.75
Day High$4.85
Day Low$4.65
52W High$12.23
52W Low$2.59
Volume—
Avg Volume208.2K
Market Cap112.10M
P/E Ratio—
EPS$-0.88
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+995.1% upside
Current
$4.65
$4.65
Target
$50.92
$50.92
$37.48
$50.92 avg
$70.07
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 76.25M | 67.19M | 17.09M |
| Net Income | -22,849,980 | -18,122,120 | -4,142,594 |
| Profit Margin | -30.0% | -28.5% | -24.3% |
| EBITDA | -14,027,527 | -11,743,171 | -7,262,848 |
| Free Cash Flow | — | — | -5,494,601 |
| Rev Growth | +13.5% | +13.5% | +9.1% |
| Debt/Equity | 1.49 | 1.49 | 0.31 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |